These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10077027)

  • 21. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10.
    Raynal I; Prigent P; Peyramaure S; Najid A; Rebuzzi C; Corot C
    Invest Radiol; 2004 Jan; 39(1):56-63. PubMed ID: 14701989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide.
    Nishimura H; Tanigawa N; Hiramatsu M; Tatsumi Y; Matsuki M; Narabayashi I
    J Am Coll Surg; 2006 Apr; 202(4):604-11. PubMed ID: 16571430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging.
    Müller K; Skepper JN; Tang TY; Graves MJ; Patterson AJ; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH
    Biomaterials; 2008 Jun; 29(17):2656-62. PubMed ID: 18377983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The MR tomography of focal liver lesions with the superparamagnetic contrast agent AMI-25 at 1.5 tesla].
    Duda SH; Laniado M; Kopp AF; Grönewäller E; Aicher KP; Pavone P; Jehle E; Claussen CD
    Rofo; 1994 Jan; 160(1):46-51. PubMed ID: 8305692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience.
    Bellin MF; Roy C; Kinkel K; Thoumas D; Zaim S; Vanel D; Tuchmann C; Richard F; Jacqmin D; Delcourt A; Challier E; Lebret T; Cluzel P
    Radiology; 1998 Jun; 207(3):799-808. PubMed ID: 9609907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study.
    Anzai Y; Piccoli CW; Outwater EK; Stanford W; Bluemke DA; Nurenberg P; Saini S; Maravilla KR; Feldman DE; Schmiedl UP; Brunberg JA; Francis IR; Harms SE; Som PM; Tempany CM;
    Radiology; 2003 Sep; 228(3):777-88. PubMed ID: 12954896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MR contrast agents in acute experimental cerebral ischemia: potential adverse impacts on neurologic outcome and infarction size.
    Doerfler A; Engelhorn T; Heiland S; Knauth M; Wanke I; Forsting M
    J Magn Reson Imaging; 2000 Apr; 11(4):418-24. PubMed ID: 10767071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research.
    Simon GH; Raatschen HJ; Wendland MF; von Vopelius-Feldt J; Fu Y; Chen MH; Daldrup-Link HE
    Acad Radiol; 2005 Sep; 12(9):1190-7. PubMed ID: 16099684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodistribution of ultrasmall iron oxide particles in the rat liver.
    Van Beers BE; Sempoux C; Materne R; Delos M; Smith AM
    J Magn Reson Imaging; 2001 Apr; 13(4):594-9. PubMed ID: 11276104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging.
    Bellin MF; Zaim S; Auberton E; Sarfati G; Duron JJ; Khayat D; Grellet J
    Radiology; 1994 Dec; 193(3):657-63. PubMed ID: 7972804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver MR imaging with iron oxides: toward consensus and clinical practice.
    Weissleder R
    Radiology; 1994 Dec; 193(3):593-5. PubMed ID: 7972790
    [No Abstract]   [Full Text] [Related]  

  • 34. Superparamagnetic iron oxide hepatic MR imaging: efficacy and safety using conventional and fast spin-echo pulse sequences.
    Schwartz LH; Seltzer SE; Tempany CM; Silverman SG; Piwnica-Worms DR; Adams DF; Herman L; Herman LA; Hooshmand R
    J Magn Reson Imaging; 1995; 5(5):566-70. PubMed ID: 8574043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
    Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
    J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging.
    Oksendal AN; Jacobsen TF; Gundersen HG; Rinck PA; Rummeny E
    Invest Radiol; 1991 Nov; 26 Suppl 1():S67-70; discussion S71. PubMed ID: 1808152
    [No Abstract]   [Full Text] [Related]  

  • 37. [Focal intrahepatic siderosis, diagnostic pitfall, iatrogenic image].
    Arteaga C; Raillat A; Salamand P; Debonne JM; Bonnet D; Martet G; Veuillet MO; Battini-Nouzille A; Briant JF
    J Radiol; 1998 Feb; 79(2):157-8. PubMed ID: 9757234
    [No Abstract]   [Full Text] [Related]  

  • 38. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging.
    Dinniwell R; Chan P; Czarnota G; Haider MA; Jhaveri K; Jewett M; Fyles A; Jaffray D; Milosevic M
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):844-51. PubMed ID: 19095369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol.
    Bluemke DA; Weber TM; Rubin D; de Lange EE; Semelka R; Redvanly RD; Chezmar J; Outwater E; Carlos R; Saini S; Holland GA; Mammone JF; Brown JJ; Milestone B; Javitt MC; Jacobs P
    Radiology; 2003 Aug; 228(2):457-64. PubMed ID: 12893904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
    Petersein J; Saini S; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.